Nasus Pharma NSRX
NYSE NSRX
$3.03 -0.21 (-6.31%)
As of: Oct 21, 2026 · 3:59 PM EDT

Nasus Pharma (NSRX) Short term Debt (2024 - 2025)

Updated

Nasus Pharma's Short term Debt came in at $2.56 million for Q2 2025.

Analysis

Nasus Pharma (NSRX) Short term Debt (2024 - 2025) Analysis & Trends

At the end of FY2024, Nasus Pharma's Short term Debt was $1.8 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Nasus Pharma 25.55 Mn 8.85 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 2.56 Mn
Dec 31, 2024 1.80 Mn
API Access

Nasus Pharma Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=NSRX&period=max&api_key=YOUR_API_KEY